^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...Metastatic or unresectable disease…Combination targeted therapy and immunotherapy if BRAF V600-activating mutation present…Dabrafenib/trametinib + pembrolizumab